2023-06-06 15:26:48 ET
Rigel Pharmaceuticals ( NASDAQ: RIGL ) added ~9% on Tuesday after announcing that the medical journal Blood Advances published data supporting Rezlidhia (olutasidenib), its FDA-approved treatment for acute myeloid leukemia (AML).
In December, Rigel ( RIGL ) launched Rezlidhia after the FDA cleared the oral therapy for adults with relapsed/ refractory AML harboring a susceptible IDH1 mutation.
In the article "Olutasidenib: from Bench to Bedside," published online in May, the authors discuss the preclinical and clinical development of olutasidenib and review the drug's positioning in the mIDH1 AML treatment space.
The article marks the second publication on Rezlidhia in Blood Advances since February, when the journal published results from the Phase 2 registrational trial for the candidate in mIDH1 R/R AML.
More on Rigel
- Rigel Pharma begun at neutral at Piper Sandler on value creation potential
- Rigel Pharmaceuticals Shows Promise With Q1 Earnings: Tavalisse And Rezlidhia Drive Growth
For further details see:
Rigel spikes after peer reviewed data on leukemia drug